Skip to main content
. 2011 Mar 8;13(2):R25. doi: 10.1186/bcr2841

Figure 5.

Figure 5

Breast cancer patients with autoantibodies to MUC1 glycopeptide combinational subset show increased time to metastasis. A, metastasis free survival with patients with autoantibodies versus no auto-antibodies (P = 0.08). B, metastasis free survival of patients with strong autoantibodies versus no antibodies (P = 0.032). C, overall survival of patients with strong autoantibodies versus no antibodies. Thick lines indicate no auto-antibodies in sera. Dotted lines indicate autoantibodies. Vertical dashes indicate censored events.